Diffusion Pharmaceuticals develops small molecule therapeutics for treating life-threatening medical conditions.
Industries BiotechnologyHealth CareTherapeuticsHeadquarters Regions East Coast, Southern US Founded Date 2001 Founders David G. Kalergis, John L. Gainer Operating Status Active Last Funding Type Post-IPO Equity
Stock Symbol NASDAQ:DFFN Company Type For Profit
Contact Email info@diffusionpharma.com Phone Number 4342200722
Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a
serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.